Telehealth
60 articles on Telehealth, researched and written by the Shotlee Editorial Team from primary sources.
Semaglutide Telehealth: From The Access Boom To Regulatory Reckoning
The rapid rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity and diabetes care, generating billions in revenue for major manufacturers while creating unprecedented demand for weight management solutions. Telehealth platforms initially emerged as a critical access channel, offering convenient prescriptions and more affordable compounded versions during national shortages. Yet by 2025 and 2026, the sector faced a sharp pivot as FDA actions resolved shortages and curtailed large-scale compounding operations.
7 min read
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy's Laboratories has paused commercial production of generic semaglutide following quality concerns with the active ingredient. Here is what patients need to know about the delay and what it means for access to GLP-1 therapy.
8 min read
Wegovy and the Wedding Dress: The Hidden Costs of Rapid Weight Loss
Prescription weight loss drugs are becoming a wedding staple, but medical experts warn of serious side effects and ethical concerns behind the trend.
9 min read
Ozempic & Wegovy Safety: The Yale Study on Online Prescribing
A recent JAMA study reveals significant gaps in medical oversight for online GLP-1 prescriptions. Discover the risks and how to ensure safe access to weight loss medications.
7 min read
Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing
New research from Yale University highlights critical gaps in the online prescribing of GLP-1 medications, raising serious concerns about patient safety and regulatory oversight.
8 min read
Ozempic & Wegovy Online: The Risky Rush to Bypass Doctor Consultations
The surge in GLP-1 medications for weight loss has led to a concerning trend: many online pharmacies are prescribing these powerful drugs with minimal to no doctor consultation, putting patients at significant risk.
6 min read
Beyond GLP-1s: Understanding the Peptide Therapy Health Craze
Peptide therapy is rapidly gaining traction far beyond the well-known GLP-1 medications. This deep dive explores the science, the 'health-maxing' movement, supply chain complexities, and the crucial regulatory landscape shaping the future of these powerful compounds.
7 min read
Beyond the Hype: Navigating the Rise of Online Peptides
A surge in injectable peptides marketed online for enhancement purposes is outpacing regulatory oversight, creating a 'grey zone' with potential public health implications. This article delves into the complexities, risks, and what consumers should understand.
6 min read
GLP-1s & Telehealth: Navigating Risks and Ensuring Safety
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
6 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
7 min read
The New Era of Nutrition: How GLP-1 Drugs Are Reshaping the Food Industry
The rapid adoption of GLP-1 agonists like Ozempic and Wegovy is forcing a profound realignment in the food and beverage industry. Initial hopes that users would eventually return to old habits have faded, replaced by a strategic pivot toward 'companion nutrition' tailored to the specific, evolving needs of individuals managing weight and metabolic health.
6 min read
GLP-1s & Eating Disorders: A Growing Concern for Patients and Doctors
The effectiveness of GLP-1 medications like Ozempic, Wegovy, and Mounjaro for weight loss has led to widespread adoption. However, a concerning trend is emerging: individuals with a history of or current eating disorders are increasingly turning to these drugs, raising alarm bells among healthcare professionals dedicated to eating disorder recovery.
9 min read
GLP-1s and Hormones: Why Rapid Weight Loss Can Intensify Menopause Symptoms
Women achieving significant weight loss on GLP-1 medications like Ozempic or Wegovy often report unexpected side effects—worsening hot flashes, sleep disruption, and mood swings—that mimic or accelerate menopause symptoms. This article explores the crucial, often overlooked, intersection between rapid fat loss and hormonal balance.
8 min read
GLP-1s, Hormones, and Weight Loss: What Women Need to Know
Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.
6 min read
Wegovy Pill Price: How to Access GLP-1 Therapy for Less
The revolutionary Wegovy pill offers a needle-free approach to GLP-1 weight loss therapy. Discover its pricing, how it compares to injectables, and how programs are working to make this effective treatment more accessible.
7 min read
GLP-1 Safety: FDA Action, TrumpRx Access & Weight Loss Drug Risks
Explore the critical safety differences between compounded GLP-1 medications and FDA-approved treatments. Understand the role of new access programs in combating unsafe alternatives.
9 min read
Hims & Hers Downgrade: What It Means for GLP-1 Weight Loss Access
Bank of America cuts Hims & Hers price target as the telehealth giant pivots from compounded GLP-1s to branded alternatives. Here is what this shift means for patients.
8 min read
Hims & Hers Q1 Earnings: What It Means for GLP-1 Access & Weight Loss
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
7 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
Lizzo's 'Weight Release': Redefining Body Autonomy & Health Goals
Lizzo's approach to 'weight release' is more than a trend; it's a profound shift towards body autonomy, prioritizing functional health and self-defined goals over external pressures. Discover how this empowering framework can guide your own wellness journey.
7 min read
FDA Proposes Curbs on Compounding Weight-Loss Drugs
The U.S. Food and Drug Administration (FDA) has proposed a significant change that could reshape the landscape of weight-loss drug accessibility. By suggesting the exclusion of key active ingredients from the list of drugs that outsourcing facilities can compound in bulk, the FDA aims to curb large-scale, unauthorized production of popular medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
7 min read
GLP-1 Therapies: Are We Testing Enough for Safe Weight Loss?
GLP-1 therapies are revolutionizing weight loss, but their widespread adoption raises critical questions about diagnostic preparedness. This article explores the growing need for robust testing frameworks to ensure the safe and effective use of these powerful medications.
8 min read
Amazon One Medical Launches GLP-1 Weight Management Program
Amazon One Medical has launched a new weight management program featuring GLP-1 medications, providing transparent pricing and dedicated primary care oversight. With GLP-1 pills starting at $25 per month with insurance or $149 cash-pay, and injectables at $299, this initiative addresses key barriers like cost. Available nationwide with rapid delivery, it builds on Amazon's growing healthcare ecosystem.
5 min read
Amazon Launches GLP-1 Weight Loss Program with Fast Access
Amazon is entering the GLP-1 weight loss market with a new program through One Medical and Amazon Pharmacy, promising fast, convenient access to treatments like Wegovy and Zepbound. With pricing as low as $25/month for insured patients and same-day delivery, it positions weight management as a chronic care solution. This could transform how patients access these popular medications.
5 min read
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
Amazon, Walmart's GLP-1 Land Grab Bigger Than Weight Loss
Amazon and Walmart are racing to dominate GLP-1 medications like Eli Lilly's new oral Foundayo, but their strategies extend far beyond filling prescriptions for weight loss. With same-day delivery, telehealth, and integrated services, they're building 'continuous care commerce' platforms. This shift promises ongoing patient support for long-term therapy success.
5 min read
Safely Buy GLP-1 Drugs Online: Key Facts Amid Ad Surge
Serena Williams' 2026 Super Bowl ad spotlighted her GLP-1 weight-loss journey, fueling massive online searches for drugs like Ozempic and Wegovy. With ads bombarding daily life and insurance often falling short, a booming online market offers cheaper options—but at what risk? Here's what you need to know to safely buy GLP-1 drugs online.
5 min read
Wegovy Pill Cost: Get It for $149/Month via WeightWatchers Med+
The new FDA-approved Wegovy pill is now available at just $149 per month for starter doses via WeightWatchers Med+, making GLP-1 weight loss therapy more affordable. This self-pay pricing beats typical injectable costs, but it's limited to 1.5mg and 4mg doses for the first four months. Discover eligibility, comparisons, and how to get started before the offer ends April 15.
5 min read
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules
Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.
5 min read
Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
4 min read
Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy
A prominent cardiologist has filed a whistleblower lawsuit against UPMC alleging racist texts and CEO conflicts. Meanwhile, U.S. blood pressure control remains below pre-pandemic levels, per new data. GLP-1 drugs during pregnancy show promising maternal benefits with no rise in fetal risks, according to a meta-analysis.
6 min read
RFK Jr. Misrepresents Ex-FDA Officials in Push to Lift Peptide Ban
Health Secretary RFK Jr. is pushing to lift the FDA's ban on 19 peptides used in compounding pharmacies, claiming the decision was illegal with no safety signals. But former FDA officials, including Janet Woodcock, say he misrepresents their views amid documented risks like immune reactions and trial fatalities. As demand surges via influencers, recent illnesses highlight the stakes in this regulatory battle.
6 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
FDA Approves Foundayo: GLP-1 Weight Loss Pill with Fewer Use Restrictions
Eli Lilly's Foundayo, a new GLP-1 weight loss pill, just received FDA approval with key advantages: take it anytime without food or water restrictions. Backed by trials showing 12% body weight loss over 72 weeks, it aims to make obesity treatment more accessible. Compare pricing, side effects, and how it stacks up against Wegovy and injectables.
5 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
Hims & Hers Surges After RFK Jr. Pushes Peptide Access on Joe Rogan
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
5 min read
Peptide Gold Rush: Deregulation Set to Supercharge Shadow Industry
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
4 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
GLP-1 Therapies: Risks and Rewards Across Conditions
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
5 min read
What to Do When Tirzepatide Stops Working: Shift to Retatrutide
If Tirzepatide worked initially but now you've hit a plateau, it's not failure—it's metabolic adaptation signaling the next phase. California Trim Clinic is leading the shift to retatrutide, a triple-pathway therapy targeting energy expenditure for sustained results. Patients are moving beyond plateaus with physician-guided care.
4 min read
DCGI Intensifies Crackdown on Unauthorized GLP-1 Weight-Loss Drug Sales
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
4 min read
Hims & Hers Stock: Costly Wegovy Deal Challenges
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
4 min read
GLP-1 Microdosers Chase Longevity: Survey Insights
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
5 min read
Behavioral Adherence Tools Key to GLP-1 Weight Loss Success: New Data
As GLP-1 medication use surges, a Weight Watchers report reveals medication alone isn't enough for lasting weight loss. Weight Loss Buddy emerges as a vital tool, combining AI-driven guidance and peer accountability to boost adherence and outcomes. This shift highlights the need for behavioral infrastructure in obesity treatment.
4 min read
Is Ozempic Behind Charles Barkley's Weight Loss? Slim Look Stuns in March Mad...
Charles Barkley's noticeably slimmer figure courtside during March Madness 2026 has sparked widespread speculation: Is Ozempic behind his weight loss? The NBA legend dropped nearly 90 pounds using GLP-1 drugs like Mounjaro and Zepbound, combined with diet and exercise. Fans are stunned, but Barkley credits hard work over hype.
5 min read
Stopping GLP-1 Drugs May Raise Heart Disease Risk, Study Finds
Popular GLP-1 drugs like semaglutide and tirzepatide offer heart health benefits for type 2 diabetes patients, but stopping them may reverse these gains. A Washington University study of over 333,000 veterans revealed up to 22% higher risk of heart attacks and strokes after discontinuation. Continuous use provides up to 18% risk reduction—here's what it means for long-term treatment.
5 min read
Florida Man Charged for Illegally Selling Off-Brand Ozempic
A St. Johns County man, Adam K. Taylor, is now facing federal misdemeanor charges for misbranding and selling off-brand versions of Ozempic (semaglutide) and other GLP-1 drugs without prescriptions. Operating AKT Labs as 'research purposes only,' he instructed undercover officers on weight loss use. This case highlights dangers of unregulated peptides sourced from China.
5 min read
Hims & Hers Opens $149 Wegovy & Ozempic Waitlist via Novo Deal
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read
Healthier Happy Selects CoreAge Rx as Top Tirzepatide Online Destination
Independent health platform Healthier Happy has chosen CoreAge Rx as its preferred destination for tirzepatide online, highlighting its physician-supervised telehealth model, straightforward pricing, and direct-to-home delivery. This recognition underscores CoreAge Rx's role in simplifying access to GLP-1 therapies like tirzepatide and semaglutide for metabolic health.
5 min read
Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
5 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Deutsche Bank Reiterates Buy on Eli Lilly Stock on GLP-1 Growth
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
5 min read
Mass. Patients Lose GLP-1 Coverage: $500/Month or Weight Regain Fear
After losing insurance coverage for GLP-1 drugs like Zepbound, Massachusetts patients are grappling with $500 monthly costs or the fear of regaining lost weight. Stories from Tierno, Markert, and others highlight the struggle, as doctors warn of health risks from discontinuation. Discover the coverage changes, patient impacts, and potential paths forward.
5 min read